The development of new therapies for chronic diseases, such as diabetic kidney disease, will continue to be hampered by lack of sufficient biomarkers that will provide insights and will be responsive to treatment interventions. The recent application of metabolomic technologies, such as nuclear magnetic resonance and mass spectroscopy, have allowed a large scale analysis of small molecules to be interrogated in a targeted or untargeted manner. Recent advances from both human and animal studies that have arisen from metabolomic analysis has been the recognition that mitochondrial function and fatty acid oxidation play key roles in the development and progression of diabetic kidney disease. Although many challenges remain for validation of the technology for clinical chronic kidney disease, there will very likely be ongoing major contributions of metabolomics to develop new biochemical understanding for diabetic and chronic kidney disease. The clinical application of metabolomics and accompanying bioinformatic tools will likely be a cornerstone of personalized medicine triumphs for chronic kidney disease.
展开▼
